AI in Cardiology Market (2026-2036)

The growth of this market is mainly driven by a regulatory architecture that gives this specialty its own classification regulation and a separate product code for each condition a model is cleared to flag, which turns every additional condition into a distinct clearance and a distinct product that can be sold into the same installed base, by the volume of cardiac data already being acquired for other reasons and available for reanalysis, since an electrocardiogram recorded before surgery and an echocardiogram ordered for a murmur both carry signal about conditions nobody was looking for, and by coronary computed tomography software that has obtained its own procedure codes and now substitutes for an invasive test rather than adding a step. Reanalysis of data that has already been paid for is the lowest-cost route to a new clinical finding anywhere in medicine, and that economics is the reason this market grows faster than cardiology spending as a whole.

However, factors such as the absence of a settled payment mechanism for software delivered as a service, the concentration of earned revenue in the few products that hold their own procedure codes, the scope of a cleared claim that suggests a likelihood in order to prompt referral rather than producing a diagnostic-quality result, and the downstream testing that a positive output generates rather than replaces are expected to restrain the growth of this market to some extent. The agency that funds most of this activity sought comment on how to pay for software delivered as a service and finalised no policy, so a hospital buying detection software in most categories is buying an operating expense against a benefit it must capture itself, and the purchaser is funding case-finding rather than cost avoidance.

21 CFR 870.2380, the class II regulation for cardiovascular machine learning-based notification software, under which a cleared device employs machine learning techniques to suggest the likelihood of a cardiovascular disease or condition in order to support referral or follow-up, evaluates one condition using one or more non-invasive physiological inputs, is intended to guide further testing rather than to produce diagnostic-quality results, and is not designed to detect arrhythmias applies to this specialty alone among the fields where machine learning has reached clinical use, and the agency has issued ten product codes issued under that regulation, covering cardiovascular conditions generally under product code QXO, coronary artery disease under QXX, reduced ejection fraction under QYE, pulmonary hypertension under SAT, atrial fibrillation risk prediction under SBQ, hypertension under SFR, cardiac amyloidosis under SHP, aortic stenosis under SII, valvular regurgitation under SIJ and cardiac hypertrophy under SIK, each reviewed by the cardiovascular panel through the 510(k) pathway. No other clinical area carries a regulation that proliferates a product code for each condition detected, and the consequence is that the market is segmented by condition at the regulatory level rather than by the analytical technique or by the data type. A vendor holding a clearance for reduced ejection fraction does not thereby hold one for cardiac amyloidosis even where the same signal and the same model family produce both outputs, so expansion proceeds condition by condition and each addition is a submission, a validation dataset and a separate commercial proposition sold into an installed base the vendor already has.

Software under this regulation suggests a likelihood in order to support referral or follow-up, evaluates a single condition from non-invasive physiological inputs, is intended to guide further testing rather than to produce a diagnostic-quality result, and is excluded from arrhythmia detection, which sits under the electrocardiograph classifications instead. A positive output therefore generates an echocardiogram, a cardiac magnetic resonance study or a specialist appointment rather than concluding the question, so the product increases downstream activity and the purchaser is buying case-finding. In a fee-for-service setting that downstream activity is revenue and the software pays for itself through the studies it prompts, while in a capitated or budget-limited setting the same output is cost, and that difference accounts for much of the variation in adoption between health systems and between countries.

The Centers for Medicare & Medicaid Services calendar year 2026 hospital outpatient prospective payment system final rule, published on 21 November 2025, in which the agency solicited comments from the public on payment policies for software as a service under the outpatient system, stated that it received many comments on future payment methodologies for such services, finalised no payment policy for them and said it will consider the comments received for future rulemaking, having also sought comment on the same question in the calendar year 2026 physician fee schedule proposed rule, so payment for most of this software has no settled mechanism. A hospital buying artificial intelligence software for cardiology in most categories is buying an operating expense justified against a benefit it must capture itself, whether in avoided transfers, shortened length of stay or additional appropriate procedures, and the few products earning at scale are those that obtained procedure codes of their own. Coronary computed tomography analysis is the clearest case, where 21 CFR 870.1415, the class II classification for coronary vascular physiologic simulation software, product code PJA, cleared through the 510(k) pathway and intended to aid in the identification of functionally significant cardiovascular disease underpins a service that substitutes for invasive angiography in selected patients rather than adding to the pathway, which is the one value proposition a payer has historically been willing to fund directly.

21 CFR 870.2800, the class II classification that separates an ambulatory electrocardiograph with an analysis algorithm, product code MLO, from an ambulatory electrocardiograph without analysis, product code MWJ, alongside 21 CFR 870.2345 for electrocardiograph software intended for over-the-counter use, product code QDA governs the largest installed data source. An electrocardiogram is the cheapest cardiac test, is acquired in enormous volume for reasons unrelated to the condition a model later detects, and exists in archives going back decades with linked outcomes, which is why the earliest and still the broadest set of cleared cardiovascular machine learning products take the electrocardiogram as their input. The separation in the classification between a recorder with an analysis algorithm and one without, and the existence of a distinct classification for electrocardiograph software intended for over-the-counter use, together mark the boundary between clinical and consumer supply, and that boundary is where most of the regulatory attention in this market now sits.

21 CFR 892.2050, the class II classification for automated radiological image processing software, product code QIH, whose definition covers artificial intelligence software using nonadaptive machine learning and excludes adaptive artificial intelligence algorithms, and 21 CFR 892.2055, the class II classification for radiological machine learning based quantitative imaging software with change control plan, product code QVD are the classifications imaging-derived products reach the market under, and the difference between them matters commercially, because the older classification excludes adaptive algorithms while the newer one names a change control plan in the device name itself. A vendor whose product sits under the newer classification has a documented route to updating a model without returning for a fresh clearance each time, and a vendor under the older one ships a frozen model. Echocardiography and cardiac magnetic resonance analysis both run through these imaging classifications while the condition-specific cardiovascular regulation covers the notification claim, so a single commercial product frequently carries clearances under two regulations with different updating positions.

The European Union Artificial Intelligence Act, which entered into force on 1 August 2024 and became generally applicable on 2 August 2026, and under which high-risk artificial intelligence systems embedded in products regulated by the sectoral legislation listed in Annex I, which includes medical devices, apply from 2 August 2028 following the extension of that transition period by the AI Omnibus, while high-risk use cases in the areas listed in Annex III apply from 2 December 2027 sets the European timetable, and products are placed on that market as medical device software under the Medical Device Regulation. The extension of the transition for systems embedded in regulated products means the device regulation rather than the artificial intelligence framework remains the binding European requirement through most of the forecast period, so notified body capacity and clinical evidence expectations govern entry. European health systems are also predominantly budget-limited rather than fee-for-service, which inverts the economics of case-finding software relative to the United States and is the reason adoption in Europe has concentrated in products that reduce an existing activity rather than in products that identify additional patients.